Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Scilex Holding CoSCLX · Entity 7345 | Director | October 17, 2024 | October 18, 2024 |
| Silence Therapeutics plcSLN · Entity 5028 | Director | January 02, 2026 | January 06, 2026 |
| Sorrento Therapeutics, Inc.SRNE · Entity 109201 | Director | August 30, 2021 | August 30, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Scilex Holding Co
Report date October 17, 2024 · Filed October 18, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,000 |
Reported balance
After 2024-10-17 transaction · row 1
1 source rowRow 1 · 2024-10-17 · Purchase · Acquired 2,000 · Balance 2,000 F1: Open market purchase by the reporting person of 2,000 shares of common stock, par value $0.0001 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: Open market purchase by the reporting person of 2,000 shares of common stock, par value $0.0001 per share.
Silence Therapeutics plc
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.05 · Expires 2036-01-02 | Direct | 90,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 90,000 · Balance 90,000 F1: This option shall vest in equal monthly installments over a one-year period measured from one month following January 2, 2026, subject to the Reporting Person's continuous service as of each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest in equal monthly installments over a one-year period measured from one month following January 2, 2026, subject to the Reporting Person's continuous service as of each applicable vesting date.
Sorrento Therapeutics, Inc.
Report date August 30, 2021 · Filed August 30, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.86 · Expires 2031-08-30 | Direct | 250,000 |
Reported balance
After 2021-08-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-08-30 · Grant · Acquired 250,000 · Balance 250,000 F1: 1/48th of the original number of shares subject to this option shall vest and become exercisable on September 30, 2021, and 1/48th of the original number of shares subject to the option shall vest following each one month of service thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the original number of shares subject to this option shall vest and become exercisable on September 30, 2021, and 1/48th of the original number of shares subject to the option shall vest following each one month of service thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 6, 2026 21:15 UTC | Silence Therapeutics plc SLN · Entity 5028 | GrantShare Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0001717972-26-000003 · form4-01062026_040101.xml · derivative · entry 1 Lemus David · CIK 0001717972 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Ordinary Shares · 90,000 shares Expires 2036-01-02 F1 · derivative.exercise_date: This option shall vest in equal monthly installments over a one-year period measured from one month following January 2, 2026, subject to the Reporting Person's continuous service as of each applicable vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:15 UTC | Silence Therapeutics plc SLN · Entity 5028 | GrantShare Option (Right to Buy) · Derivative | 48,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001415889-25-000746 · form4-01062025_040109.xml · derivative · entry 1 Lemus David · CIK 0001717972 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,000 Underlying: Ordinary Shares · 48,000 shares Expires 2035-01-02 F1 · derivative.exercise_date: This option shall vest in equal monthly installments over a three-year period measured from one month following January 2, 2025, subject to the Reporting Person's continuous service as of each applicable vesting date. Read SEC document |
| October 17, 2024 Filed Oct 18, 2024 09:10 UTC | Scilex Holding Co SCLX · Entity 7345 | PurchaseCommon Stock | 2,000 | $0.90 | $1,800.00 |
DisclosureSEC source: 0000950170-24-115450 · ownership.xml · nonDerivative · entry 1 Lemus David · CIK 0001717972 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 F1 · kind: Open market purchase by the reporting person of 2,000 shares of common stock, par value $0.0001 per share. Read SEC document |
| March 15, 2024 Filed Jun 26, 2024 21:29 UTC | Scilex Holding Co SCLX · Entity 7345 | GrantNonstatutory Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.37 | $0.00 |
DisclosureSEC source: 0000950170-24-078114 · ownership.xml · derivative · entry 1 Lemus David · CIK 0001717972 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-03-15 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| January 17, 2023 Filed Jan 17, 2023 17:28 UTC | Scilex Holding Co SCLX · Entity 7345 | GrantNonstatutory Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $8.08 | $0.00 |
DisclosureSEC source: 0000899243-23-001872 · doc4.xml · derivative · entry 1 Lemus David · CIK 0001717972 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2033-01-17 F1 · derivative.exercise_date: 1/48th of the subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Party's continued service to the Issuer through each such vesting date. Read SEC document |
| August 30, 2021 Filed Aug 30, 2021 20:13 UTC | Sorrento Therapeutics, Inc. SRNE · Entity 109201 | GrantStock option (right to buy) · Derivative | 250,000 | $0.00 Strike: $8.86 | $0.00 |
DisclosureSEC source: 0001209191-21-053983 · doc4.xml · derivative · entry 1 Lemus David · CIK 0001717972 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2031-08-30 F1 · derivative.exercise_date: 1/48th of the original number of shares subject to this option shall vest and become exercisable on September 30, 2021, and 1/48th of the original number of shares subject to the option shall vest following each one month of service thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| June 15, 2020 Filed Jun 15, 2020 18:10 UTC | Sorrento Therapeutics, Inc. SRNE · Entity 109201 | GrantStock Options · Derivative | 100,000 | $0.00 Strike: $4.89 | $0.00 |
DisclosureSEC source: 0000850261-20-000045 · wf-form4_159225900329337.xml · derivative · entry 1 Lemus David · CIK 0001717972 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-06-15 F1 · derivative.exercise_date: 1/12th of the original number of shares subject to this option shall vest and become exercisable on July 15, 2020, and 1/12th of the original number of shares subject to the option shall vest following each one month of service thereafter, subject to the Reporting Person's continued service on the Issuer's board of directors on each such date. Read SEC document |
| April 19, 2019 Filed Apr 23, 2019 21:02 UTC | Sorrento Therapeutics, Inc. SRNE · Entity 109201 | GrantStock Options · Derivative | 70,000 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0000850261-19-000015 · wf-form4_155606775780923.xml · derivative · entry 1 Lemus David · CIK 0001717972 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2029-04-19 F1 · derivative.exercise_date: 1/12 of the original number of shares subject to this option shall vest and become exercisable on May 14, 2019 and following each one month of service thereafter, subject to the Reporting Person's continued service on the Issuer's board of directors on each such date. Read SEC document |
| November 26, 2018 Filed Nov 27, 2018 19:47 UTC | Sorrento Therapeutics, Inc. SRNE · Entity 109201 | GrantStock Options · Derivative | 35,000 | $0.00 Strike: $3.57 | $0.00 |
DisclosureSEC source: 0000850261-18-000043 · wf-form4_154336605538232.xml · derivative · entry 1 Lemus David · CIK 0001717972 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2028-11-26 F1 · derivative.exercise_date: 1/12 of the original number of shares subject to this option shall vest and become exercisable following each one month of service thereafter, subject to the Reporting Person's continued service on the Issuer's board of directors on each such date. Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 19:22 UTC | Sorrento Therapeutics, Inc. SRNE · Entity 109201 | GrantStock Options · Derivative | 35,000 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001144204-17-059793 · tv479803_4.xml · derivative · entry 1 Lemus David · CIK 0001717972 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2027-11-14 F1 · derivative.exercise_date: 1/12 of the original number of shares subject to this option is immediately vested and exercisable. 1/12 of the original number of shares subject to this option shall vest and become exercisable on November 26, 2017 and 1/12 of the original number of shares subject to the option shall vest following each one month of service thereafter, subject to the Reporting Person's continued service on the Issuer's board of directors on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.